A recent study indicates that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt traditional lifestyle programs.
Research printed in a prominent medical journal points out that while overweight individuals often shed about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"Users buying such treatments must be informed of the danger of quick rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting weight in about a year and a half.
Analyzing Approaches
The research, which looked at dozens of trials involving thousands of participants, compared the effects of the injectable medications with older methods.
Researchers point out that individuals who shed pounds through lifestyle changes alone usually experience a more gradual creep back—approximately 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Experts suggest the mode of action of the jabs accounts for the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is uncontrolled, making binge eating much more probable."
A Chronic Disease?
The NHS advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, given the high risk of weight regain, the therapy is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the findings "underscore the persistent character of obesity," similar to managing conditions like hypertension.
Patient Accounts
Users who have discontinued the jabs explain a powerful resurgence of hunger.
"I experienced something activating and you become ravenous," recalled a patient.
The struggle is exacerbated if users have not adopted lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is greater among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while the jabs are potent agents for weight loss, they are not a standalone cure and lasting health benefits hinges on ongoing behavioural support.
